Beta Bionics reported its seventh quarter as a public company, and the second quarter of fiscal 2026 was the print in which the pharmacy channel stopped being a side story. Net sales of $32.0 million were up 38% year over year, but the load-bearing observation was inside that number: pharmacy benefit plan (PBP) channel sales of $11.6 million rose 153% from a year-ago $4.6 million and now represent 36% of total revenue, while the legacy durable medical equipment (DME) channel grew a more measured 9%. The PBP channel exists because the iLet bionic pancreas was, until recently, almost entirely a DME product - sold through distributors who buy the hardware and bill insurance - and the move into pharmacy reimbursement is the structural reason the installed customer base went from 15,298 users at the end of 2024 to 35,011 at the end of 2025. The cost of that pivot is showing up in operating expense: sales and marketing alone rose 58% year over year to $24.6 million, more than three-quarters of total revenue, and the company posted a GAAP operating loss of $25.6 million and an adjusted EBITDA loss of $17.7 million. The quarter re-raised the gross margin guide (now 58.5% to 59.5% for the year) and reaffirmed the revenue range ($131M–$136M, midpoint $133.5M, +33% to +36% over 2025's $100.3M), but the next twelve months will be defined by three dates management named, not by the quarter: pivotal trial enrollment for the iLet in adults with type 2 diabetes, full commercial launch of the Mint patch pump targeted for the end of the second quarter of 2027, and the additional feasibility trial for the bihormonal system. The question the quarter answers is whether the PBP growth rate is structurally compounding, and the question the next four quarters answer is whether the pipeline clocks can hold.